Plant Name: Rabdosia angustifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| MGAM; | |
| TDP1; BLM; HSD17B1; ALOX15; AOX1; | |
| MAPK1; ABL1; EGFR; | |
| CA2; CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| MAOA; | |
| HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| SLCO1B3; SLCO1B1; | |
| NPC1; RAB9A; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.320E-10 | 9.578E-07 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.811E-10 | 1.530E-06 | ALOX15, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.667E-09 | 4.538E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.077E-08 | 1.804E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.444E-08 | 2.107E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.991E-08 | 2.281E-05 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.961E-08 | 3.083E-05 | ABCC1, CA2, CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.687E-08 | 4.639E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.917E-08 | 6.275E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.693E-08 | 7.281E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.929E-08 | 7.722E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.125E-07 | 8.444E-05 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.320E-07 | 9.255E-05 | ABL1, BLM, CYP1A1, CYP1B1, EGFR, ESR1, MAPK1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.527E-07 | 2.347E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.628E-07 | 3.914E-04 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.033E-06 | 4.499E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.084E-06 | 4.541E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.084E-06 | 4.541E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.217E-06 | 4.908E-04 | CYP1A1, CYP1B1, CYP3A4, ESR1, HSD17B1 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.217E-06 | 4.908E-04 | ABL1, CYP1B1, EGFR, MAPK1, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.007E-06 | 9.922E-04 | ESR1, ESR2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 5.565E-06 | 1.616E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.614E-06 | 2.256E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 9.012E-06 | 2.256E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.012E-06 | 2.256E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.012E-06 | 2.256E-03 | CYP1A1, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.574E-05 | 3.498E-03 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.800E-05 | 3.806E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.800E-05 | 3.806E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.165E-05 | 4.326E-03 | CYP1A2, EGFR, MAPK1 |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 2.274E-05 | 4.501E-03 | CA2, CA7, MAPK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.997E-05 | 5.600E-03 | CYP1A1, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:1900274; regulation of phospholipase C activity | 3.419E-05 | 6.309E-03 | ABL1, EGFR, ESR1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.491E-05 | 7.887E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 5.830E-05 | 9.917E-03 | ABL1, BLM, EGFR, MAPK1, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0006766; vitamin metabolic process | 5.875E-05 | 9.917E-03 | ABCC1, AOX1, CYP1A1, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.585E-09 | 9.811E-07 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.487E-08 | 2.228E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.019E-08 | 2.987E-06 | CYP2C9; CYP1A2; CYP1A1; AOX1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.086E-07 | 2.987E-06 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.444E-07 | 2.987E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.255E-07 | 2.987E-06 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.630E-08 | 1.215E-06 | CA12; CA2; CA4; CA7 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.595E-07 | 4.296E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.604E-07 | 2.987E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.945E-06 | 7.368E-05 | MAPK1; TP53; HIF1A; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.663E-06 | 1.309E-04 | ABCC1; ABL1; CYP1B1; MAPK1; TP53; EGFR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.246E-05 | 2.679E-04 | MAPK1; TP53; HIF1A; ESR1; EGFR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.674E-05 | 2.846E-04 | CYP2C9; MGAM; MAOA; HSD17B1; TBXAS1; CYP1A2; ALOX15; CYP1A1; AOX1; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.337E-05 | 2.679E-04 | MAPK1; ESR1; EGFR; ESR2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.796E-05 | 3.771E-04 | CYP2C9; MAOA; ALOX15; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.657E-05 | 4.082E-04 | MAPK1; TP53; ESR1; HIF1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.170E-04 | 8.716E-04 | MAPK1; TP53; EGFR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.330E-05 | 6.895E-04 | HSD17B1; CYP1A1; CYP1B1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.578E-05 | 4.082E-04 | MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.371E-05 | 7.349E-04 | MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.824E-04 | 1.236E-03 | MAPK1; TP53; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.204E-04 | 2.674E-03 | ABL1; MAPK1; HIF1A; TP53; EGFR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.909E-04 | 1.237E-03 | MAPK1; TP53; EGFR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.585E-04 | 1.125E-03 | CYP2C9; ALOX15; TBXAS1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.371E-04 | 1.472E-03 | MAPK1; TP53; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.471E-04 | 1.473E-03 | MAPK1; ESR1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.574E-04 | 1.475E-03 | ABL1; MAPK1; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.613E-04 | 2.455E-03 | MAPK1; TP53; EGFR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.316E-04 | 2.382E-03 | ABL1; MAPK1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 6.676E-04 | 3.291E-03 | MAPK1; HIF1A; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.068E-04 | 3.291E-03 | MAPK1; HIF1A; EGFR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.101E-03 | 4.580E-03 | ABL1; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.101E-03 | 4.580E-03 | ABCC1; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.480E-03 | 5.958E-03 | MAPK1; TP53; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.662E-03 | 2.256E-02 | ABL1; MAPK1; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.158E-03 | 2.903E-02 | MAPK1; TP53; EGFR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.668E-03 | 1.739E-02 | MAPK1; HIF1A |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.045E-02 | 3.114E-02 | MAPK1; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.976E-03 | 1.808E-02 | MAPK1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.621E-03 | 1.948E-02 | MAPK1; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.018E-03 | 2.324E-02 | MAPK1; EGFR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.800E-03 | 3.042E-02 | MAPK1; EGFR |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.456E-03 | 1.936E-02 | ABL1; MAPK1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.538E-03 | 9.695E-03 | ABCC1; ABCG2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.107E-03 | 4.580E-03 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 9.587E-04 | 4.329E-03 | MAPK1; EGFR |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.611E-03 | 6.318E-03 | MAOA; AOX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.940E-04 | 3.291E-03 | CA2; CA4 |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 1.016E-02 | 3.089E-02 | AOX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.472E-03 | 2.744E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; ABL1; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| C00-D49: Neoplasms | Breast cancer | C50 | EGFR; EGFR; EGFR; ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | MGAM |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; ABL1; EGFR |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |